Custo Direto com Tecnologias Para Manejo da Colostomia Definitiva em um Serviço Especializado / Direct Cost of Technologies for Management of Definitive Colostomy in a Specialized Service / Costo Directo de Tecnologías Para el Manejo de la Colostomía Definitiva en un Servicio Especializado

Objetivos:Identificar o custo direto de um serviço especializado com o uso de equipamentos coletores e adjuvantes e compará-lo com o custo simulado da autoirrigação intestinal em pessoas com colostomia definitiva. Método: Estudo descritivo-exploratório conduzido por meio da abordagem quantitativa nos moldes de estudo de casos múltiplos. A amostra por conveniência foi composta de 22 participantes cadastrados em um serviço especializado do norte de Minas Gerais. A coleta de dados foi realizada em prontuários do período de janeiro de 2019 a janeiro de 2020. Resultados: Dos participantes, 59,1% apresentaram complicações relacionadas à estomia e pele periestomia. Em relação aos equipamentos coletores/adjuvantes, o custo variou de 2.340,00 a R$ 5.535,00, custo médio de R$ 4.050,01 e desvio padrão amostral de R$ 770,31. O custo direto médio com autoirrigação de colostomia foi de R$ 3.793,44. Conclusão: O custo direto médio dos equipamentos coletores/adjuvantes foi superior ao da autoirrigação de colostomia, impactado pela presença de complicações e pelo valor do protetor de colostomia.

Objectives:To identify the direct cost of a specialized service with the use of collection equipment and adjuvants and to compare it with the simulated cost of intestinal self-irrigation in people with permanent colostomy. Method: Descriptive-exploratory study conducted through a quantitative approach in the form of multiple-case studies. The convenience sample consisted of 22 participants registered in a specialized service in the north of Minas Gerais, Brazil. Data collection was carried out in medical records from January 2019 to January 2020. Results: Among the participants, 59.1% had complications related to the ostomy and peristomal skin. Regarding collector/adjuvant equipment, the cost ranged from R$ 2,340.00 to R$ 5,535.00, average cost of R$ 4,050.01, and sample standard deviation of R$ 770.31. The average direct cost with colostomy self-irrigation was R$ 3,793.44. Conclusion: The average direct cost of collection/adjuvant equipment was higher than that of colostomy self-irrigation, impacted by the presence of complications and the value of the colostomy protector.

Objetivos:Identificar o custo direto de um serviço especializado com o uso de equipamentos coletores e adjuvantes e compará-lo com o custo simulado da autoirrigação intestinal em pessoas com colostomia definitiva. Método: Estudo descritivo-exploratório conduzido por meio da abordagem quantitativa nos moldes de estudo de casos múltiplos. A amostra por conveniência foi composta de 22 participantes cadastrados em um serviço especializado do norte de Minas Gerais. A coleta de dados foi realizada em prontuários do período de janeiro de 2019 a janeiro de 2020. Resultados: Dos participantes, 59,1% apresentaram complicações relacionadas à estomia e pele periestomia. Em relação aos equipamentos coletores/adjuvantes, o custo variou de 2.340,00 a R$ 5.535,00, custo médio de R$ 4.050,01 e desvio padrão amostral de R$ 770,31. O custo direto médio com autoirrigação de colostomia foi de R$ 3.793,44. Conclusão: O custo direto médio dos equipamentos coletores/adjuvantes foi superior ao da autoirrigação de colostomia, impactado pela presença de complicações e pelo valor do protetor de colostomia.

Contribution margin per hour of operating room to reallocate unutilized operating room time: a cost-effectiveness analysis

Abstract Background and objectives: Contribution margin per hour (CMH) has been proposed in healthcare systems to increase the profitability of operating suites. The aim of our study is to propose a simple and reproducible model to calculate CMH and to increase cost-effectiveness. Methods: For the ten most commonly performed surgical procedures at our Institution, we prospectively collected their diagnosis-related group (DRG) reimbursement, variable costs and mean procedural time. We quantified the portion of total staffed operating room time to be reallocated with a minimal risk of overrun. Moreover, we calculated the total CMH with a random reallocation on a first come-first served basis. Finally, prioritizing procedures with higher CMH, we ran a simulation by calculating the total CMH. Results: Over a two-months period, we identified 14.5 hours of unutilized operating room to reallocate. In the case of a random ''first come -first serve'' basis, the total earnings were 87,117 United States dollars (USD). Conversely, with a reallocation which prioritized procedures with a high CMH, it was possible to earn 140,444 USD (p < 0.001). Conclusion: Surgical activity may be one of the most profitable activities for hospitals, but a cost-effective management requires a comprehension of its cost profile. Reallocation of unused operating room time according to CMH may represent a simple, reproducible and reliable tool for elective cases on a waiting list. In our experience, it helped improving the operating suite cost-effectiveness.

Costos directos y calidad de vida de los pacientes con glaucoma en Paraguay / Direct costs and quality of life of patients with glaucoma in Paraguay

Introducción:El glaucoma constituyeun problema de salud pública por su alta prevalencia, los costos directos y la calidad de vida deteriorada de los pacientes que lo sufre. Objetivo:Determinar los costos directos y calidad de vida de los pacientes adultos con glaucoma atendidos en la Clínica Central de la Fundación Visión de noviembre 2022 a febrero 2023. Material y métodos:estudio observacional, descriptivo, corte transversal que incluyó pacientes con diagnóstico de glaucoma por muestreo por conveniencia. Resultados:Se incluyeron 140 pacientes entre 29 y 90 años, 52,9% femenino, 43,6% primaria incompleta, 32,1% desempleado. El tratamiento médico se realizó en el 81%, laser en 42% y procedimiento quirúrgico en 32%. Se informó un gasto promedio anual de 3.639.800gs ($ 503.93) por paciente. El estado emocional afectado se informó en el 35,7% de los pacientes, y calidad de vida deteriorada en el 48,6%; el 55% de los pacientes tiene dependencia para sus cuidados personales. Conclusión:El glaucoma implica grandes costos directos debido al tratamiento, además los pacientes tienen deterioro de la calidad de vida.Palabras Clave:glaucoma; costos de la atención en salud; distrés psicológico; calidad de vida

Introduction.Glaucoma is still a public health problem due to its high prevalence, the socioeconomic impact it entails for the patient who suffers from it, which decreases the quality of life. Objective:To determine the direct costs and quality of life of adult patients treated WITH glaucoma in the Fundación Visión Central Clinic from November 2022 to February 2023. Material and methods:observational, descriptive, cross-sectional study that included patients diagnosed with glaucoma by sampling by convenience. Results:140 patients between 29 and 90 years old were included, 52.9% female, 43.6% incomplete primary education, 32.1% unemployed. Medical treatment was performed in 81%, laser in 42% and surgical procedure in 32%. An average annual expense of 3,639,800gs ($503.93) per patient was reported. Emotional affectation was reported in 35.7% of the patients, and 43.5% deteriorated quality of life; 55% of the patients has dependency on personal care. Conclusion:Glaucoma involves large direct costs, due to treatment, in addition patients have deterioration in the quality of life.Key words:glaucoma; health care costs;psychological distress; quality of life

Pancreatitis aguda: costos en un hospital universitario en Chile / Acute pancreatitis: costs in a university hospital in Chile

Background: Acute pancreatitis (AP) is a common disease. There is no information available on the costs of treatment in Chile. Aim: To obtain information on the cost of hospitalization for AP and identify the factors that influence the account, to analyze health insurance coverage and the economic charge for the patient. Patients and Method: Retrospective and descriptive study. Patients treated at the Hospital Clínico Universidad de Chile with diagnosis of AP between May 1, 2014 and April 30, 2016 were included. The clinical records were reviewed after the patient's discharge. Demographic characteristics, clinical evolution, the account issued, the insurance payment and patient's copayment were registered. Results: In the period studied, 176 patients (90 women) were discharged with diagnosis of AP. The dominant etiology was biliary in 61%. According to the Atlanta 2013 classification, 78.4% of the cases were mild, 10.2% moderate, and 11.4% severe. 3 patients (1.7%) died. The median cost in Chilean pesos was $ 2,537,918 (1,383,151-3,897,673) (p25-75). The total sum of the accounts of 176 patients was $ 885,261,241, with an average of $ 5,029,893. The average coverage of the health system (FONASA or ISAPRE) was $ 4,293,113, leaving a copayment of $ 801,661. The final cost was related to the severity of the disease, the length of hospitalization and the need for a high-complexity bed. Discussion: Hospitalization costs for PA are high. It is advisable to rationalize the critical care bed indication.

Introducción: La pancreatitis aguda (PA) es una patología frecuente. No hay información disponible del costo de su tratamiento en Chile. Objetivo: Obtener información del costo de hospitalización por PA, identificar los factores que influyen en la cuenta, estudiar la cobertura por seguros de salud y el cargo económico para el paciente. Pacientes y Métodos: Estudio retrospectivo, descriptivo. Se incluyeron pacientes tratados en el Hospital Clínico Universidad de Chile con diagnóstico de PA entre 01 de mayo de 2014 y 30 de abril de 2016. Las fichas clínicas fueron revisadas después del alta del paciente, se registraron sus características demográficas, evolución clínica, la cuenta emitida, el pago del seguro y el copago del paciente. Resultados: En el periodo estudiado 176 pacientes (90 mujeres) fueron dados de alta con diagnóstico de PA. La etiología dominante fue biliar en 61% . Según la clasificación de Atlanta 2013, 78,4% de los casos fueron leves, 10,2% moderados y 11,4% severos. Fallecieron 3 pacientes (1,7%). La mediana de costos fue de $2.537.918 (1.383.151-3.897.673) (p25-75). La suma total de las cuentas de 176 pacientes fue de $ 885.261.241, con un promedio de $ 5.029.893. La cobertura promedio del sistema de salud (FONASA o ISAPRE) fue de $ 4.293.113 dejando un copago de $ 801.661. El costo final se correlacionó con la severidad de la enfermedad, la duración de la hospitalización y la necesidad de cama de alta complejidad. Discusión: Los costos de hospitalización por PA son elevados. Es recomendable racionalizar la indicación de cama crítica.

Cout réel de la prise en charge des cancers du col de l'utérus en radiothérapie au Cameroun / The real cost of the management of cervical cancers by radiotherapy in Cameroon

Introduction. Le cancer du col utérin est le deuxième cancer de la femme au Cameroun. La radiothérapie reste une des modalités thérapeutiques phares dans la prise en charge de cette pathologie et l'État participe en y apportant une subvention. Toutefois, plusieurs patientes n'accèdent pas au traitement en raison des difficultés financières. Notre objectif était d'évaluer le coût réel de la prise en charge afin de servir de support aux politiques d'aide aux patientes. Méthodologie. Uneétude descriptive, transversale portant sur les patientes traitées en radiothérapie à l'Hôpital Général de Douala pour cancer du col de l'utérus a été réalisée d'octobre 2020 à janvier 2021.Résultats. Au total 35 dossiers de patientes ont été inclus. Lespatientes avaient de faibles revenus (<108.810 XAF /mois, 51,3%), étaient sans assurance maladie (88,6%), provenant en majorité des villes hors de Douala (54,3%), avec des cancers localement évolués. Le coût global moyen du traitement était de 511 264 XAF+/-103479 XAF (779,42 +/-157,75 euros) pour chaque patiente. La durée moyenne de traitement était de 57,34 jours, avec un nombre médian de 27 séances. Les frais supplémentaires pendant le traitement provenaient de la chimiothérapie, de la gestion des effets secondaires, notamment des transfusions sanguines, et du bilan de suivi. Plus de la moitié des patientes ont eu besoin d'une prise en charge supplémentaire par chimiothérapie ou chirurgie. Conclusion. La prise en charge du cancer du col utérin par radiothérapie est coûteuse et peu accessible à la majorité des patientes Camerounaises.

Introduction.Cervix cancer is the second cancer among women in Cameroon. Radiotherapy is often warranted in its management. Many patients do not access treatment due to financial difficulties. Our objective was to assess the real cost of care in order to support patient assistance policies. Methodology. A descriptive cross over study of women treated by radiotherapy at the Douala General Hospital from October 2020 to January 2021 was conducted. Results. A total number of 35 patient files were included in the study. Patients generally had low income (<108.810 XAF /month), without medical insurance, lived out of Douala, and were diagnosed at locally advanced stages of their disease. Average cost of treatment for radiotherapy alone was 511,264 XAF +/-103,479 XAF. Average duration of treatment was 57.34 days, with a median number of 27 sessions. Extra cost came from chemotherapy, management of side effects especially from blood transfusions, and imaging. More than half of the patients required additional expense for adjunct chemotherapy or surgery. Conclusion. The total cost of treatment for cervix cancer by radiotherapy is quite expensive, and not accessible to the average Cameroonian

Exploring cost drivers for improving disease management: the case of type 2 diabetes at a tertiary hospital in Burundi, Africa

Globally, the covid-19 pandemic has seriously impacted access to healthcare facilities across the world, although there is little evidence on how the pandemic affects the use of essential healthcare in the world. This study sought to evaluate the impact of the covid-19 pandemic on antenatal indicators in the region of Guelmim Oued Noun, Morocco using the interrupted time-series analysis. The aggregated data was delivered by regional health authorities covering the period from January 2017 to December 2020. The descriptive results revealed a steady decline after the Covid-19 pandemic in Antenatal indicators. The results of the regression model showed a negative impact of the pandemic on the antenatal recruitment rate (ß2 = - 16.14; p < 0.01), recruitment rate of women in antenatal visits the 1st quarter of pregnancy (ß2 = -2.09; p < 0.01), antenatal visit completion rate (ß2= -18.10, p>0.05), average number of visits/pregnancies (ß2 = -15.65, p<0,05). The effect of thecovid-19 pandemic on antenatal rates was significant for almost the indicators studied. Future studies should be focused on the impact of the pandemic on postnatal and immunization services on the national scale.

Analysis of the direct economic burden of measles cases and its influencing factors in Shanghai from 2017 to 2019 / 中华预防医学杂志

Objective: To analyze the direct economic burden caused by measles cases in Shanghai from 2017 to 2019 and its influencing factors. Methods: A total of 161 laboratory-confirmed measles cases reported from January 1, 2017, to December 31, 2019, in Shanghai were included in the study through the "Measles Surveillance Information Reporting and Management System" of the "China Disease Surveillance Information Reporting and Management System". Through telephone follow-up and consulting hospital data, the basic information of population, medical treatment situation, medical treatment costs and other information were collected, and the direct economic burden of cases was calculated, including registration fees, examination fees, hospitalization fees, medical fees and other disease treatment expenses, as well as transportation and other expenses of cases. The multiple linear regression model was used to analyze the main influencing factors of the direct economic burden. Results: The age of 161 measles cases M (Q1, Q3) was 28.21 (13.33, 37.00) years. Male cases (56.52%) were more than female cases (43.48%). The largest number of cases was≥18 years old (70.81%). The total direct economic burden of 161 measles cases was 540 851.14 yuan, and the per capita direct economic burden was 3 359.32 yuan. The direct economic burden M (Q1, Q3) was 873.00 (245.01, 4 014.79) yuan per person. The results of multiple linear regression model analysis showed that compared with other and unknown occupations, central areas and non-hospitalized cases, the direct economic burden of measles cases was higher in scattered children, childcare children, students, and cadre staff in the occupational distribution, suburban areas and hospitalized, with the coefficient of β (95%CI) values of 0.388 (0.150-0.627), 0.297 (0.025-0.569), 0.327 (0.148-0.506) and 1.031 (0.853-1.209), respectively (all P values<0.05). Conclusion: The direct economic burden of some measles cases in Shanghai is relatively high. Occupation, area of residence and hospitalization are the main factors influencing the direct economic burden of measles cases.

El costo esperado de cáncer en Chile / The expected cost of cancer in Chile

BACKGROUND: Cancer is a public health priority in Chile. AIM: To estimate the expected annual cost of cancer in Chile, due to direct costs of health services, working allowances and indirect costs for productivity losses. MATERIAL AND METHODS: We undertook an ascendent costing methodology to calculate direct costs. We built diagnostic, treatment and follow-up cost baskets for each cancer type. Further, we estimated the expenditure due to sick leave subsidies. Both estimates were performed either for the public or private sector. Costs related to productivity loss were estimated using the human capital approach, incorporating disease related absenteeism premature deaths. The time frame for all estimates was one year. RESULTS: The annual expected costs attributed to cancer was $1,557 billion of Chilean pesos. The health services expected annual costs were $1,436 billion, 67% of which are spent on five cancer groups (digestive, hematologic, respiratory, breast and urinary tract). The expected costs of sick leave subsidies and productivity loss were $48 and $71 billion, respectively. CONCLUSIONS: Cancer generates costs to the health system, which obliges health planners to allocate a significant proportion of the health budget to this disease. The expected costs estimated in this study are equivalent to 8.9% of all health expenditures and 0.69% of the Gross Domestic Product. This study provides an updated reference for future research, such as those aimed at evaluating the current health policies in cancer.

Análisis del impacto presupuestal en Colombia de la prueba de HPV con genotipificación comparada con la citología / Budget impact analysis of primary screening with the HPV test and genotyping against conventional cytology in Colombia

Introducción. La detección del virus del papiloma humano mediante la combinación de la prueba de HPV y otras técnicas como la citología, ha demostrado su eficacia en el diagnóstico y tratamiento oportuno de lesiones asociadas con el cáncer de cuello uterino. Objetivo. Estimar el impacto presupuestal de la estrategia de detección temprana del HPV mediante la prueba de genotipificación combinada con la citología en comparación con la citología convencional, en mujeres de 30 a 65 años participantes en el programa de tamizaje de cáncer de cuello uterino en una Entidad Administradora del Plan de Beneficios en salud (EAPB) en Colombia. Materiales y métodos. Utilizando un árbol de decisiones y un modelo de Markov, se estimaron las implicaciones clínicas y los costos directos anuales de dos ciclos de tamizaje, diagnóstico y tratamiento, en una cohorte de mujeres. Las prevalencias de los resultados clínicos y los costos se tomaron de la base de datos de una EAPB y la información de la progresión, persistencia y regresión de los estados de salud provinieron del estudio ATHENA. Resultados. El esquema de tamizaje con la prueba de HPV, la genotipificación y la citología resultó en un ahorro de costos comparado con la citología convencional. El costo promedio por ciclo de tamizaje con la prueba de HPV se estimó en COP $129'201.363 y con la citología en COP $186'309.952, es decir, un ahorro de COP $57'108.589 (30,7 %). Conclusión. La implementación de la estrategia de tamizaje evaluada sugiere que habría ahorros derivados de la detección temprana de los estados de salud asociados con el desarrollo de cáncer de cuello uterino.

Introduction: The detection of the human papillomavirus (HPV) through the combination of the HPV test and other techniques such as cytology has impacted the detection and timely treatment of lesions associated with cervical cancer. Objective: To estimate the budgetary impact of the strategy of early detection of HPV with DNA test genotyping with reflex cytology versus conventional cytology in women aged 30 to 65 years attending the cervical cancer screening program at a health benefit managing entity in Colombia. Materials and methods: Using a decision tree and a Markov model, the clinical implications and direct costs of screening, diagnosis, and treatment were estimated in a cohort of women. The analysis considered two screening cycles and their annual costs. The data on the prevalence of clinical results and the costs were taken from the health managing entity. The information on the progression, persistence, and regression of the health states were taken from the ATHENA study. Results: The screening scheme with the HPV test, genotyping, and reflex cytology compared to conventional cytology was cost-saving. The average cost per screening cycle with the HPV test was estimated at COP $ 129,201,363 and with cytology at COP $ 186,309,952, i.e., a saving of COP $ 57,108,589 (30.7%). Conclusion: The implementation of the screening strategy under evaluation suggests prospective savings derived from the early detection of health states associated with the development of cervical cancer.

A pandemia de COVID-19 e o seu impacto à saúde planetária / The COVID-19 pandemic and its impact on planetary health

A pandemia de COVID-19 deu ao mundo uma imagem clara do que é uma crise multidimensional em escala planetária, revelando o papel central que ocupa o setor de saúde e as profundas desigualdades no acesso aos cuidados em saúde que existem entre os diferentes países, e dentro de cada um deles. Melhorar os efeitos ambientais do setor e reduzir as emissões de gases de efeito estufa pode não apenas melhorar a saúde de todos, mas também reduzir os custos com os cuidados em saúde. O setor de saúde de cada país libera direta e indiretamente gases de efeito estufa ao fornecer seus serviços e ao comprar produtos, serviços e tecnologias em uma cadeia de fornecimento de carbono intensivo. Educar os profissionais de saúde mais profundamente sobre os efeitos das mudanças climáticas pode levar a práticas clínicas mais sustentáveis, melhorando os resultados para os pacientes e fornecendo um impulso substancial para aumentar os esforços para reduzir as emissões de carbono. O setor da saúde deve assumir a responsabilidade por sua pegada climática respondendo à crescente emergência climática, não apenas prestando assistência aos doentes, feridos ou moribundos como resultado da crise climática e suas causas, mas também fazendo a prevenção primária e reduzindo drasticamente suas próprias emissões.

The COVID-19 pandemic has painted a clear picture of what a multidimensional planetary crisis is, revealing the central role played by the health sector and the deep inequalities in access to health care that exist between and within each country. Decreasing the environmental effects of the health sector and reducing greenhouse gas emission may not only improve people's health, but also reduce health care costs. The health care sectors around the world directly and indirectly release greenhouse gases by providing their services and purchasing products, services, and technologies within a carbon-intensive supply chain. Further educating health care professionals about the effects of climate change may lead to more sustainable clinical practices, improving patient outcomes and providing substantial impetus to increased efforts to reduce carbon emission. The health sector must take responsibility for its climate footprint by responding to the growing climate emergency not only by assisting the sick, injured, or dying from the climate crisis, but also by doing primary prevention and drastically reducing its own carbon emission.

Costo de atención de recién nacidos con peso 1500 gramos en el Hospital Penna, Bahía Blanca, Argentina / Costs for the health care of newborns weighing up to 1500 g at Penna Hospital, Bahía Blanca, Argentina

INTRODUCCIÓN: Los sistemas de costos por servicio hospitalario permiten evaluar la eficiencia en la utilización de recursos y son la base para realizar estudios comparativos entre grupos de pacientes con características diferenciales. La internación en Neonatología de niños de bajo peso al nacer presenta especial interés por su complejidad y alto costo. El objetivo fue estimar los costos directos del día de internación en el Servicio de Neonatología del Hospital Interzonal Dr. José Penna de pacientes con peso al ingreso menor o igual a 1500 g en 2019. MÉTODOS: Se realizó un estudio retrospectivo, para el cual se relevaron datos del Servicio de Neonatología y de las áreas de compras y personal del Hospital. Se estimó el costo promedio por día de internación y por egreso del total del Servicio y de los recién nacidos con peso de hasta 1500 g. RESULTADOS: El estudio se realizó sobre 489 egresos. El costo directo promedio por día de internación fue de $17.755. Para el grupo de peso ≤ 1500 g, el promedio de días de internación fue de 55,9 y el costo promedio por egreso, de $992.191; para ≤ 1000 g, de 80,6 y $1.430.229, respectivamente. Se evidenció un fuerte impacto del bajo peso al nacer: el 8% de los egresos con vida de Neonatología genera el 33% de los costos del proceso de internación neonatal. DISCUSIÓN: Es importante realizar estudios de costos por servicio hospitalario, en especial por grupos de casos, a fin de generar información útil para la toma de decisiones.

Carga de la enfermedad y costos en salud por la exposición a mercurio: revisión de alcance / Burden of disease and health costs from mercury exposure: Scoping review

Resumen Introducción: El mercurio circula por el aire; persiste en suelos, sedimentos y agua, y causa efectos en la salud humana. Las mujeres en edad fértil y los neonatos son la población más vulnerable. Objetivo: Analizar las evidencias sobre la carga de enfermedad ocasionada por la exposición a mercurio, así como el impacto económico sobre el sistema de salud. Metodología: Revisión de alcance de la literatura, de las bases de datos PUBMED y EPISTEMONIKOS, búsqueda manual de documentos técnicos de entidades oficiales de diferentes continentes. Resultados: Se identificaron 311 registros en bases de datos y 4 en búsqueda manual en entidades oficiales; 19 artículos fueron incluidos. Discusión: Predomina la afectación del desarrollo neurológico y cognitivo en niños de madres expuestas y lactantes. Los costos se midieron por la pérdida del coeficiente intelectual. Conclusión: Efectos en salud por la exposición a metilmercurio se traducen en gastos para la sociedad y los sistemas de salud.

Abstract Introduction: Mercury circulates through the air, persists in soils, sediments and water, and can affect human health. Women of childbearing age and newborns are the most vulnerable population. Objective: To analyze the evidence on the burden of disease caused by mercury exposure, as well as the economic impact on the health system. Methodology: Review of the literature, PUBMED and EPISTEMONIKOS databases, manual search of technical documents of official entities from different continents. Results: A total of 311 records were identified in databases and four in manual searches from official entities; 19 articles were included. Discussion: Neurological and cognitive development in children of exposed mothers and infants are more predominant. Costs were measured by IQ loss. Conclusion: Health effects of methylmercury exposure translate into costs for society and health systems.

A Brazilian cost-utility analysis of trabecular micro-bypass with iStent inject® for the treatment of open-angle glaucoma / Análise de custo-utilidade do implante trabecular iStent inject® para o tratamento do glaucoma de ângulo aberto no Brasil

ABSTRACT Purpose To evaluate the cost-utility of the iStent inject® for the treatment of mild-to-moderate open-angle glaucoma (OAG) within the Brazilian Unified Health System (SUS). Methods A Markov model was developed, in which the effectiveness outcome measure was the incremental cost-effectiveness ratio (ICER: R$ / QALY quality-adjusted life-year). Direct medical costs were obtained from the SUS perspective. The base case comprised of a hypothetical cohort of patients with OAG using topical medication and being managed according to the Clinical Protocol and Therapeutic Guidelines (PCDT) and a real-world setting based on data from Datasus. The model's robustness through sensitivity analyses was tested. Results In the PCDT base case setting, the trabecular micro-bypass implant provided gains of 0.47 QALYs and an ICER of R$7,996.66/QALY compared to treatment with topical medication. In the real-world setting based on data from Datasus, the trabecular micro-bypass implant, provided gains of 0.47 QALYs and an ICER of R$4,485.68/QALY compared to treatment with topical medication. The results were robust to sensitivity analyses. Conclusion Incorporating iStent inject® to SUS provides an improvement in the patient's quality of life with an additional cost that warrants the benefit provided to patients. Results may be considered cost-effective compared to topical medication.

RESUMO Objetivo Avaliar a relação custo-utilidade do iStent inject® para o tratamento do glaucoma de ângulo aberto leve a moderado no Sistema Único de Saúde. Métodos Foi desenvolvido um modelo de Markov, no qual a medida de resultado de efetividade foi a razão custo-efetividade incremental (razão de custo-efetividade incremental: R$/ano de vida ajustado pela qualidade). Os custos médicos diretos foram obtidos por meio da perspectiva do Sistema Único de Saúde. O caso base foi composto de uma coorte hipotética de pacientes com glaucoma de ângulo aberto em uso de medicação tópica tratados de acordo com o Protocolo Clínico e Diretrizes Terapêuticas e um cenário do mundo real baseado em dados do Departamento de Informática do Sistema Único de Saúde. Foi testada a robustez do modelo por meio de análises de sensibilidade. Resultados No cenário base do Protocolo Clínico e Diretrizes Terapêuticas, o implante trabecular micro-bypass proporcionou ganhos de 0,47 ano de vida ajustado pela qualidade e razão de custo-efetividade incremental de R$7.996,66/ano de vida ajustado pela qualidade em relação ao tratamento com medicação tópica. No cenário real baseado em dados do Departamento de Informática do Sistema Único de Saúde, o implante trabecular proporcionou ganhos de 0,47 ano de vida ajustado pela qualidade e razão de custo-efetividade incremental de R$ 4.485,68/ano de vida ajustado pela qualidade em relação ao tratamento com medicação tópica. Os resultados foram robustos para análises de sensibilidade. Conclusão A incorporação do iStent inject® ao Sistema Único de Saúde proporciona melhora na qualidade de vida do paciente com um custo adicional que garante o benefício proporcionado a eles. Os resultados podem ser considerados custo-efetivos em comparação com a medicação tópica.

Impacto económico de los egresos hospitalarios asociados a cáncer gástrico en las regiones del Maule, La Araucanía y Aysén durante los años 2015-2020 / Economic impact of hospital discharges associated with gastric cancer in del Maule, La Araucanía and Aysén regions during years 2015-2020

Introduction: Gastric cancer (GC) represents one of the highest incidences in the world and in Chile, registering one of the highest mortality rates with a significant economic impact. Objective: Examine the economic expenditure (EE) associated with bed-days due to GC in patients older than 45 years according to the year of the hospital discharge, during the years 2015-2020 in the regions of Maule, La Araucanía, and Aysén del General Carlos Ibáñez del Campo. Material y methods: Our ecological study is focused on a sample of patients who registered a discharge due to GC was applied (n=3,391). Data extraction was performed from the Department of Statistics and Health Information. Results: During the period of analysis, was recorded an expense of $508,995,025, with 2017 being the year with the highest value of $111,321,220. The largest EE was concentrated in La Araucanía with $265,802,005 and the smallest in Aysén with $23,646,555. Discussion: There is a genetic predisposition to GC in the Mapuche population, which resides in southern Chile. In addition, the lower EE is associated with the female sex because estrogens interfere in processes that are related to a lower predisposition for the development of GC. It is recommended to extend the study to other regions of Chile in order to extrapolate the results to the national level and to enrich the available literature.

Introducción: El cáncer gástrico (CG) representa una de las mayores incidencias en el mundo y en Chile, registrando una de las tasas más altas de mortalidad con un impacto económico importante. Objetivo: Examinar el gasto económico (GE) asociados a días-cama por CG en pacientes mayores a 45 años según año de egreso hospitalario, durante los años 2015-2020 en las regiones del Maule, La Araucanía y Aysén del General Carlos Ibáñez del Campo. Materiales y métodos: Se aplicó un estudio ecológico focalizado en una muestra de pacientes que registran un egreso a causa de CG (n=3.391). La extracción de datos se realizó a partir del Departamento de Estadística e Información de Salud. Resultados: En el período se registró un gasto de $508.995.025, siendo el año 2017 el que presentó el mayor con un valor de $111.321.220. El mayor GE se concentró en La Araucanía con $265.802.005 y el menor en Aysén con $23.646.555. Discusión: Existe una mayor predisposición genética al CG en la población mapuche residente en el sur de Chile y el menor GE se asocia al sexo femenino debido a que los estrógenos interfieren en procesos que se relacionan con una menor predisposición para el desarrollo de CG. Se recomienda ampliar el estudio a otras regiones de Chile para poder extrapolar los resultados a nivel nacional y enriquecer la literatura disponible.

Aspects socio-économiques de la prise en charge des hépatites virales chroniques en Côte-d'Ivoire / Socio-economic aspects of the management of chronic viral hepatitis in Côte-d'Ivoire

Contexte et objectifs. Les hépatites virales chroniques constituent un problème de santé publique en Côte-d'Ivoire. Très peu de malades accèdent au traitement en raison des coûts élevés du bilan et du traitement. L'objectif de la présente étude était d'évaluer les coûts du bilan et du traitement des hépatites virales chroniques. Méthodes. Il s'agissait d'une étude observationnelle transversale analytique réalisée, du 1er mars 2019 au 31 juillet 2019, en consultation d'hépato-gastroentérologie du CHU de Yopougon. Les variables étudiées étaient les paramètres sociodémographiques et économiques. Résultats. Au total, 136 patients (hommes 53, 6 %, âge moyen de 42 ans ± 12,2) ont été inclus. Plus de la moitié des patients (63,3 %) avaient un revenu mensuel n'excédant pas 490.39 USD. Le coût du bilan initial était de 223.13 USD et de 351.14 USD respectivement, pour l'hépatite virale B et C. Le ténofovir et l'interféron pégylé étaient gratuits. Le traitement par sofosbuvir + velpastavir coûtait 593.37 USD. Le bilan de suivi annuel était estimé à 237.02 USD pour l'hépatite virale B, 225.58 USD pour l'hépatite virale C. Conclusion. Le bilan et le traitement des hépatites virales chroniques ont un coût prohibitif pour les patients malgré la couverture maladie universelle.

Context and objectives. Chronic viral hepatitis is a public health problem in Côte-d'Ivoire. A significant number of patients have little access to treatment due to the high costs of assessment and treatment. The objective of our study was to evaluate the costs of assessments and treatment of chronic viral hepatitis. Methods. This was an analytical cross-sectional observational study from March 1, 2019 to July 31, 2019 in the HepatoGastroenterology Consultation Service at the Yopougon University Hospital. The variables studied were socio-demographic and economic parameters. Results. 136 patients (men 53.6 %, average age 42 ± 12.2 years) were included. More than half of the patients (63.3 %) had a monthly income not exceeding 490.39 USD. The cost of the initial assessment was 223.13 USD and 351.14 USD for viral hepatitis B and C, respectively. Tenofovir and pegylated interferon were free of charge. Treatment with sofosbuvir + velpastavir cost 593.37 USD. The annual follow-up assessment was estimated at 237.02 USD for viral hepatitis B and 225.58 USD for viral hepatitis C. Conclusion. The assessment and treatment of chronic viral hepatitis have a cost that remains high for patients despite the universal health coverage.

Average direct costs of outpatient, hospital, and home care provided to patients with chronic wounds / Costos directos promedios de la atención ambulatoria, hospitalaria y domiciliaria prestada a pacientes con heridas crónicas / Custos diretos médios da assistência ambulatorial, hospitalar e domiciliar prestada aos pacientes com feridas crônicas

ABSTRACT Objective: To analyze the average direct costs of outpatient, hospital, and home care provided to patients with chronic wounds. Method: Quantitative, exploratory-descriptive case study, carried out in a Comprehensive Wound Care Unit. Costs were obtained by multiplying the time spent by professionals by the unit cost of labor in the respective category, adding to the costs of materials and topical therapies. Results: Outpatient care costs corresponded to US$4.25 (SD ± 7.60), hospital care to US$3.87 (SD ± 17.27), and home care to US$3.47 (SD ± 5.73). In these three modalities, direct costs with dressings and medical consultations were the most representative: US$7.76 (SD ± 9.46) and US$6.61 (SD ± 6.54); US$7.06 (SD ± 24.16) and US$15.60 (SD ± 0.00); US$4.09 (SD ± 5.28) and US$15.60 (SD ± 0.00), respectively. Conclusion: Considering comprehensive care for patients with chronic wounds, the mean total direct cost was US$10.28 (SD ± 17.21), with the outpatient modality being the most representative in its composition. There was a statistically significant difference (p value = 0.000) between the costs of home and outpatient, home and hospital, and outpatient and hospital care.

RESUMEN Objetivo: Analizar los costos directos promedios de la atención ambulatoria, hospitalaria y domiciliaria prestada a pacientes con heridas crónicas. Método: Investigación cuantitativa, exploratoria-descriptiva, del tipo estudio de caso, realizada en una Unidad de Atención Integral de Heridas. Los costos se obtuvieron al multiplicar el tiempo dedicado por los profesionales por el costo unitario de la mano de obra en la respectiva categoría, sumado a los costos de materiales y terapias tópicas. Resultados: Los costos de atención ambulatoria correspondieron a US$ 4,25 (DE ± 7,60), hospitalaria a US$ 3,87 (DE ± 17,27) y atención domiciliaria a US$ 3,47 (DE ± 5,73). En estas tres modalidades, los costos directos con apósitos y consultas médicas fueron los más representativos: US$7,76 (DE ± 9,46) y US$6,61 (DE ± 6,54); US$7,06 (DE ± 24,16) y US$15,60 (DE ± 0,00); US$4,09 (DE ± 5,28) y US$15,60 (DE ± 0,00), respectivamente. Conclusión: Considerando la atención integral a pacientes con heridas crónicas, el costo directo promedio total fue de US$ 10,28 (DE ± 17,21), siendo la modalidad ambulatoria la más representativa en su composición. Hubo una diferencia estadísticamente significativa (p-valor = 0,000) entre los costos de atención domiciliaria y ambulatoria; domiciliaria y hospitalaria y, por fin, ambulatoria y hospitalaria.

RESUMO Objetivo: Analisar os custos diretos médios da assistência ambulatorial, hospitalar e domiciliar prestada aos pacientes com feridas crônicas. Método: Pesquisa quantitativa, exploratório-descritiva, do tipo estudo de caso, realizada numa Unidade de Tratamento Integral de Ferida. Obtiveram-se os custos multiplicando-se o tempo despendido pelos profissionais pelo custo unitário da mão de obra da respectiva categoria, somando-se aos custos dos materiais e terapias tópicas. Resultados: Os custos da assistência ambulatorial corresponderam a US$4,25 (DP ± 7,60), da hospitalar a US$3,87 (DP ± 17,27) e da domiciliar a US$3,47 (DP ± 5,73). Nessas três modalidades, os custos diretos com os curativos e consultas médicas foram os mais representativos: US$7,76 (DP ± 9,46) e US$6,61 (DP ± 6,54); US$7,06 (DP ± 24,16) e US$15,60 (DP ± 0,00); US$4,09 (DP ± 5,28) e US$15,60 (DP ± 0,00), respectivamente. Conclusão Considerando a assistência integral aos pacientes com feridas crônicas, o custo direto médio total foi de US$10,28 (DP ± 17,21), sendo a modalidade ambulatorial a mais representativa na sua composição. Constatou-se diferença estatística significante (valor p = 0,000) entre os custos da assistência domiciliar e ambulatorial, domiciliar e hospitalar e ambulatorial e hospitalar.

Process-based Management aimed at improving health care and financial results / Gestión basada en procesos visando a mejoría de los resultados asistenciales y financieros en Salud / Gestão baseada em processos visando à melhoria dos resultados assistenciais e financeiros em Saúde

ABSTRACT The limited resources allocated to the health area and the growing demands require leaders' qualified and committed performance in hospital management. In this perspective, the objective of this study is to reflect on the management practices that can be applied to hospital facilities to achieve better care and financial results. Among them, process-based management proposes an approach for continuous process improvement to achieve desired results; the method Lean Six Sigma allows identifying and eliminating waste in production processes; the continuous improvement model combines practical knowledge with the knowledge of how the system to be improved works, through observations and changes that allow its results measurement; and cost management and value-based healthcare provides for care mapping, from beginning to end, to assess what actually adds value to patients. The contributions of implementing these practices are recognized worldwide; using them, processes can be increased, improving efficiency, reducing waste, adding value to the business, increasing its revenue, and resulting in savings that can be passed on to the consumer, by improving quality.

RESUMEN Los recursos limitados destinados al área de Salud y las crecientes demandas exigen la actuación calificada y comprometida de líderes en la gestión hospitalaria. En esta perspectiva, el objetivo es reflexionar sobre las prácticas de gestión que se pueden aplicar a las instituciones hospitalarias para lograr mejores resultados asistenciales y económicos. Entre ellos, la gestión basada en procesos propone un enfoque de mejora continua de procesos para lograr los resultados deseados; el método Lean Six Sigma permite identificar y eliminar los desperdicios en los procesos productivos; el modelo de mejoría continua combina el conocimiento práctico al conocimiento del funcionamiento del sistema que se reta mejorar, a través de observaciones y cambios que permitan la medición de sus resultados; y la gestión de costes y de salud atención médica basada en el valor establece que la atención sea mapeada, desde el principio hasta el final del proceso, para evaluar lo que efectivamente es lo que agrega valor a los pacientes. Las contribuciones de implementación de esas prácticas son reconocidas a nivel mundial; con ellas se pueden incrementar los procesos, aumentando la eficiencia, reduciendo los desperdicios, agregando valor al negocio, aumentando sus ingresos y generando ahorros que pueden transferirse al consumidor, al mejorar la calidad.

RESUMO Os recursos limitados destinados à área da Saúde e as demandas crescentes requerem a atuação qualificada e compromissada dos líderes na gestão hospitalar. Nesta perspectiva, objetiva-se refletir sobre as práticas de gestão passíveis de serem aplicadas às instituições hospitalares visando o alcance de melhores resultados assistenciais e financeiros. Dentre elas, a gestão baseada em processos propõe uma abordagem para melhoria contínua dos processos a fim de alcançar os resultados desejados; o método Lean Six Sigma permite identificar e eliminar desperdícios nos processos produtivos; o modelo de melhoria contínua alia o conhecimento prático ao conhecimento do funcionamento do sistema a ser melhorado, por meio de observações e mudanças que permitam a mensuração de seus resultados; e a gestão de custos e a Saúde baseada em valor preveem que o cuidado seja mapeado, do início ao fim do processo, para avaliar o que, de fato, agrega valor aos pacientes. As contribuições da implementação dessas práticas são reconhecidas mundialmente; utilizando-as, os processos podem ser incrementados, aumentando a eficiência, reduzindo os desperdícios, agregando valor ao negócio, aumentando a sua receita e resultando em economias que podem ser repassadas ao consumidor, pela melhoria da qualidade.

Factors related to healthcare costs of road traffic accidents in Bucaramanga, Colombia / Factores relacionados con costos por atención médica de siniestros de tránsito en Bucaramanga, Colombia

ABSTRACT OBJECTIVE To determine the factors related to overall healthcare costs of road traffic accidents in Bucaramanga, Colombia. METHODS A descriptive cross-sectional study was conducted through the analysis of road traffic accident records that took place in 2019 in Bucaramanga, Colombia. Cost quartiles in dollars were compared using Pearson's chi-squared and Fisher's exact tests. Odds ratios were also calculated in logistic regression. RESULTS 3,150 road accidents were reported in 2019 involving 7,038 people, of which 812 had information related to healthcare costs in health care institutions. The median cost was 56.59 USD (RI = 29.35-140.15), average cost of 290.11 USD ± 731.22 (95%CI: 239.74-340.48). A higher possibility to be in the 4th quartile was found when persons were under 18 years of age (OR = 4.88; 95%CI: 1.30-18.32) or 46-60 years (OR = 3.66; 95%CI: 1.01-13.30), the type of vehicle involved is motorcycle (OR = 2.79; 95%CI: 1.25-6.24), bicycle (OR = 7.66; 95%CI: 2.70-21.68), having a head injury (OR = 4.50; 95%CI: 2.61-7.76) and hypothetical drunk driving (OR = 12.44; 95%CI: 2.01-76.87). CONCLUSIONS Relevant factors in healthcare costs were riding a motorcycle or bicycle, having a head injury, being under 18 years of age or 46 to 60 years of age and hypothetical drunk driving. It is important to implement prevention measures based on identified factors to reduce road accident rate and therefore, its socioeconomic costs.

RESUMEN OBJETIVO Determinar los factores relacionados con los costos generales durante la atención en salud de siniestros de tránsito en Bucaramanga, Colombia. MÉTODOS Estudio descriptivo, transversal, con análisis de registros de siniestros de tránsito durante 2019 en Bucaramanga, Colombia. Se realizó una comparación entre cuartiles de los costos en dólares con pruebas estadísticas de Chi-cuadrado de Pearson y exacta de Fisher. También, se calcularon odds ratio en regresión logística. RESULTADOS En 2019 se registraron 3.150 siniestros, con 7.038 personas involucradas, de los cuales 812 tenían información de costos generados por atención en instituciones de salud. La mediana de costos fue US$ 56,59 (RI = 29,35-140,15), promedio de US$ 290,11 ± 731,22 (IC95% 239,74-340,48). Se observó mayor posibilidad para estar en cuartil 4 de los costos si la persona tenía menos de 18 años (OR = 4,88; IC95% 1,30-18,32) o entre los 46-60 años de edad (OR = 3,66; IC95% 1,01-13,30), cuando el tipo de vehículo es la motocicleta (OR = 2,79; IC95% 1,25-6,24) y la bicicleta (OR = 7,66; IC95% 2,70-21,68), si la lesión ocurre en la cabeza (OR = 4,50; IC95% 2,61-7,76) y si la hipótesis está relacionada con embriaguez (OR = 12,44; IC95% 2,01-76,87). CONCLUSIÓN Los factores relevantes en los costos fueron la motocicleta, bicicleta, lesión en la cabeza, ser menor de 18 años o tener entre los 46 años y los 60 años y embriaguez como hipótesis. Es relevante implementar medidas de prevención según los factores identificados para disminuir la accidentalidad y, por ende, sus costos socioeconómicos.

Modelo de estimación de costos de atención integral para enfermedades trasmisibles / Comprehensive care cost estimation model for communicable diseases

Los costos de atención integral para enfermedades trasmisibles, en el régimen subsidiado o contributivo indirecto del sistema de salud del Perú., son la base para la formulación de políticas publicas para garantizar el derecho a la salud, por esto, mediante un arreglo metodologico, se construyo un modelo de estimación de costos de atención integral para enfermedades trasmisibles, el cual, es verificación y validación por expertos. Primero se priorizaron dengue, malaria, tuberculosis y enfermedad diarreica aguda como grupos de diagnósticos, de acuerdo a aspectos demográficos, determinantes sociales, indicadores de mortalidad y morbilidad. Sucesivamente se construye el modelo teorico "Costo Atención Integral (CAI) = Æ© C (Capital)+ CVI (Costo variable indireccto) + CVD (Costo variable direccto) +CC (Costo por contingencia) + CP/S (Costo paciente/sociedad), obteniendo valores estimados de 3,66+0,40 y 3,71+0,34 respectivamente para costos totales; mientras que el costo paciente/sociedad arrojaron valores de 2,98+0,49 de verificación y validación de 2,68+0,32; estimaciones indicativas que los componentes del sistema propuesto pesquisan los costos reales de los procesos de atención se salud del régimen sidsidiario, es decir alta adecuación de los procesos, utilidad de insumos y materiales, uso eficiente en los diferentes entornos del sistema; como una herramienta crucial de información para la comparación e identificación de las intervenciones de tipo preventivo más costo-efectivas(AU)

The costs of comprehensive care for communicable diseases, in the subsidized or indirect contributory regimen of the Peruvian health system, are the basis for the formulation of public policies to guarantee the right to health, for this reason, through a methodological arrangement, it was built a comprehensive care cost estimation model for communicable diseases, which is verified and validated by experts. First, dengue, malaria, tuberculosis and acute diarrheal disease were prioritized as diagnostic groups, according to demographic aspects, social determinants, mortality and morbidity indicators. Successively, the theoretical model "Comprehensive Care Cost (CCI) = Æ© C (Capital) + IVC (Indirect variable cost) + DVC (Direct variable cost) + CC (Contingency cost) + P/SC (Patient/society cost) is built , obtaining estimated values of 3.66+0.40 and 3.71+0.34 respectively for total costs; while the patient/society cost yielded values of 2.98+0.49 for verification and validation of 2.68+0.32; indicative estimates that the components of the proposed system investigate the real costs of the health care processes of the subsidiary regime, that is to say, high adequacy of the processes, usefulness of supplies and materials, efficient use in the different environments of the system; as a crucial information tool for the comparison and identification of the most cost-effective preventive interventions(AU)